Effect of growth hormone treatment on diastolic function in patients who have developed growth hormone deficiency after definitive treatment of acromegaly.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

This study was designed to investigate the effect of GH replacement on cardiac parameters in acroGHD.

Who Took Part

The study group was 23 patients.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

Main outcome measures included LV mass corrected for body surface area (LVM/BSA) and measures of diastolic dysfunction (E/A ratio and deceleration time), as assessed by echocardiography.

What Was Measured

Topics PubMed links to this paper include Acromegaly, Diastole, Hormone Replacement Therapy, Human Growth Hormone and Hypopituitarism.

Author keywords: Cardiovascular risk, Diastolic dysfunction and Growth hormone deficiency.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 23 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.